Exact Sciences Corporation (NASDAQ: EXAS) saw its stock surge 13.02% in pre-market trading on Friday, following the release of its better-than-expected first-quarter 2025 results and an upward revision of the company's full-year guidance. The molecular diagnostics company, known for its Cologuard colorectal cancer screening test, demonstrated robust growth and improved financial performance, exciting investors about its future prospects.

Exact Sciences reported Q1 revenue of $706.8 million, representing a 10.9% year-over-year increase and surpassing Wall Street's expectations of $688.64 million. The company's adjusted loss per share narrowed to $0.21, beating analysts' estimates of a $0.38 loss. Notably, Exact Sciences raised its full-year 2025 revenue guidance to a range of $3.07 billion to $3.12 billion, up from the previous forecast of $3.025 billion to $3.085 billion.

The company's strong performance was driven by several factors, including: 1. Robust growth in its Screening segment, which includes revenue from Cologuard tests, rising 14% year-over-year to $540 million. 2. The successful launch of Cologuard Plus, its next-generation colon cancer screening test. 3. Improved commercial execution, resulting in a 10% increase in sales representative productivity. 4. Progress in its product pipeline, including the development of Oncodetect, a molecular residual disease and recurrence monitoring test. Kevin Conroy, chairman and CEO of Exact Sciences, commented on the results: "Our strong first quarter results pave the way for 2025 to mark our most transformative year yet. With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained, long-term growth."